SUN PHARMACEUTICAL INDUSTRIES LTD Q4 RESULTS
Sun Pharma completes merger of Taro
As part of this merger, Sun Pharma acquired all outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates. As a result of the merger, Taro will be delisted from the NYSE and it becomes a privately held company 100% owned by Sun Pharma.
Ozempic frenzy lures rich Indians to brave the gray market
People are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying counterfeit formulas online, and importing boxes from Europe. The treatments have sparked extensive media coverage, fueling a high demand. According to Goldman Sachs Research, the anti-obesity medication market could hit $100 billion by 2030. In contrast, Indians have largely been observers in this global frenzy over the new weight-loss solutions.
Expert panel to soon weigh plan to use generics for prescription drugs
An expert committee is set to discuss the feasibility of allowing generic substitutions for prescription drugs in India. The proposal has sparked a disagreement between the Indian Pharmaceutical Alliance (IPA) and the All India Drug Action Network (AIDAN). The IPA opposes the idea, arguing that it would lead to a surge of demand from trade channels, such as general pharmacy stores, which would not benefit patients.
Stock Radar: This battery maker stock turned multibagger in a year; what should investors do?
Exide Industries has given massive returns to its investors in a year and according to experts there is more steam left in the stock. The stock has an upside of 143% in a year. After consolidating in a narrow range for the past few weeks, it gave a breakout from the same this week. The sudden rise followed by consolidation resembles a breakout above a Flag & Pole pattern.
Q4 results today: Apollo Hospitals among 895 companies to announce earnings on Thursday
Fourth quarter earnings season is wrapping up with 895 companies reporting results on Thursday. Investors keenly await Apollo Hospitals' results, expecting robust growth driven by improved ARPOB and HealthCo operations. Analysts predict up to a 68% YoY increase in net profit, with sales expected to rise by 13%.
IFB Industries Q4 Results: Profit at Rs 12 crore
IFB Industries Ltd has reported a consolidated net profit of Rs 12 crore for the fourth quarter ended March 31, 2024, helped by performance from engineering business and home appliances. The company had posted a net loss of Rs 9.94 crore for the year-ago period, according to a regulatory filing on Tuesday.
- Go To Page 1
DOMS shares rally 10% to fresh all-time high after Q4 results; brokerages increase target up to Rs 2,121
DOMS Industries witnessed a remarkable surge of 10% in its shares on Tuesday on the BSE, reaching a new all-time high of Rs 2,035. This surge followed the company's announcement of a 29.6% year-on-year (YoY) increase in its Q4 profit after tax (PAT), which amounted to Rs 46.93 crore.
Nalco Q4 Results: Profit jumps two-fold YoY to Rs 996.7 cr
State-owned Nalco on Monday reported two-fold rise in consolidated profit to Rs 996.74 crore for the March quarter on the back of lower expenses. The company had posted a consolidated profit of Rs 495 crore in the March quarter of FY23, National Aluminium Company Ltd (Nalco) said in a filing to the BSE.
DCM Shriram Industries Q4 Results: Profit rises 23% to Rs 39 crore
DCM Shriram Industries reported a 23% increase in consolidated net profit to Rs 38.64 crore for Q4 of the 2023-24 fiscal, driven by lower expenses.
Q4 results today: LIC, NMDC among 236 companies to announce earnings on Monday
236 companies, including LIC and NMDC, to announce Q4 results. LIC reported a 49% rise in Q3 earnings, while NMDC saw a 62% increase in consolidated net profit.
Torrent Pharma Q4 Results: Net profit jumps 56% YoY to Rs 449 crore
Torrent Pharmaceuticals Ltd on Friday reported a 56.45 per cent jump in consolidated net profit to Rs 449 crore in the March quarter, riding on higher revenue.
Hindalco Q4 results today: Here's what to expect from the metals major
Hindalco Industries likely to report muted revenues in Q4FY24 despite higher profitability. Novelis expected to see improved earnings. Investors await management guidance on domestic aluminum demand and hedging position.
Sun Pharma shares tumble 5% but brokerages raise target up to Rs 1,785. Should you buy, sell or hold?
In Thursday's trading session on the BSE, shares of Sun Pharmaceutical Industries declined by 5%, reaching the day's low of Rs 1,467. This drop occurred despite the company reporting a 34% year-on-year (YoY) increase in its Q4 profit to Rs 2,654.6 crore, with revenue rising by 10.1% YoY to Rs. 11,813 crore in Q4FY24.
Q4 results today: ITC, IndiGo among 181 companies to announce earnings on Thursday
181 companies, including IndiGo and ITC, will announce their quarterly earnings for Jan-Mar 2024. IndiGo is expected to post healthy earnings, while ITC may see muted revenue growth.
Grasim Q4 Results: Net profit jumps 39% YoY to Rs 1,908 crore; revenue rises 13%
Grasim Q4 Results: The net profit stood at Rs 1,369 crore in the last year quarter. Revenue from operations increased 13% year-on-year to Rs 37,727 crore in the reporting period, compared with Rs 4,873 crore in the corresponding period of previous year.
Sun Pharma net profit jumps 34% YoY to Rs 2,654.6 crore in Q4FY24
Sun Pharma's Q4FY24 net profit rises 34% YoY to Rs 2654.6 crore, driven by increased sales of global specialty products. Interim dividend of Rs. 5 declared for FY24.
Sun Pharma Q4 Results: Profit jumps 34% YoY to Rs 2,654 crore, meets Street estimates
Sun Pharma Q4 Results: The company's revenue rose 10% year-on-year to Rs 11,983 crore in the reporting quarter. It was Rs 10,931 crore a year ago. Its board has approved a final dividend of Rs 5 per share, which will be paid within the prescribed timeline. India formulations sales were Rs 3,707 crore for the fourth quarter, showing growth of 10% over Q4 last year and accounted for 31.4% of total consolidated sales for the quarter.
Q4 results today: Sun Pharma, Nykaa, Paytm among 162 companies to declare earnings on Wednesday
162 companies to report Q4 earnings on Wednesday. Nykaa expects 24% BPC and Fashion GMV growth, while Paytm faces a revenue decline from RBI actions. Analysts also predict pressure from discounting and lower advertising income.
Q4 results this week: ITC, ONGC, Sun Pharma, Nykaa, Ircon International and IRFC
ITC, ONGC, IRFC, Ircon International, BHEL, BEL, Sun Pharma, Nykaa, Tata Investment Corporation, Hindalco, Ashok Leyland, and Divi's lab will be releasing their March quarter report cards this week.
Balkrishna Industries shares jump 5% post Q4 results
Balkrishna Industries Share Price: Shares of BKT surged 5% on Saturday to its fresh 52-week high of Rs 2,798.95 supported by the company’s solid fourth quarter performance. Its net profit soared 88% while revenue jumped 16% to Rs 2,697 crore on the back of a sales volume of 82,085 MT.
GSK Pharma Q4 Results: Net profit rises 46% YoY at Rs 194.48 crore
The company had posted a net profit of Rs 133.43 crore in the corresponding quarter of the previous fiscal, GlaxoSmithKline Pharmaceuticals (GSK Pharma) said in a regulatory filing.
Berger Paints India Q4 Results: Standalone net profit falls over 7% YoY to Rs 181.6 crore
Berger Paints India has crossed Rs 10,000 crore in sales and Rs 1,000 crore in profit in 2023-24 (Apr-Mar), helped by double-digit growth in sales volume and operating profit growing by nearly a fourth.
Apar Industries shares zoom 8% after company reports Q4 results, announces Rs 51 dividend
Apar Industries recorded a fresh 52-week high on Tuesday apparently propelled by its Q4 revenue growth of 9% YoY. Its PAT, however, declined 3% YoY. The stock has zoomed 208% in the last one year.
Alembic Pharma Q4 Results: Posts higher profit on strong N.America sales
Alembic Pharma Q4 Results: Indian generic drugmaker Alembic Pharma reported a 17% rise in fourth-quarter profit on Thursday, driven by strong sales, especially in the key North American market.
Dr Reddy's Q4 Results: Net profit jumps 36% YoY to Rs 1307 crore
Dr Reddy's has reported a 36% year-on-year jump in quarterly net profit, helped by increase in volumes of base business, new product launches, partially offset by price erosion in certain markets.
Lupin share price drops 5% post Q4 earnings
Lupin Share Price: Its revenue from operations in the same period jumped 12% YoY to Rs 4,961 crore as against Rs 4430 crore in the corresponding period of last year.
Dr Reddy's Q4 Preview: PAT may rise over 50% YoY on strong US sales
Based on an average estimate from four brokerages, revenue from operations during the January-March 2023 period is anticipated to increase by up to 18% year-on-year. Concurrently, the net profit after tax is expected to experience a robust surge of up to 54% year-on-year.
Britannia Industries Q4 Results: Cons PAT declines 4% YoY to Rs 538 crore; dividend declared at Rs 73.5 per share
Britannia Q4 Results: The PAT was in line with the Street's estimates, which predicted the same at Rs 537 crore. The total revenue reported in the January-March quarter stood at Rs 4,069.36 crore, which was up nearly 1% over Rs 4,023.18 crore reported by in the corresponding quarter of the last financial year.
Load More
